Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020

SUMMARY

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts. It stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 4, 6 and 2 respectively.

Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Solid Tumor, Breast Cancer, Rheumatoid Arthritis, Melanoma, Metastatic Colorectal Cancer, Muscle Invasive Bladder Cancer (MIBC), Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Ankylosing Spondylitis (Bekhterev's Disease), Axial Spondyloarthritis, Bile Duct Cancer (Cholangiocarcinoma), Chronic Myelomonocytic Leukemia (CMML), Colon Carcinoma, Colorectal Cancer, Cutaneous Angiosarcoma, Cytokine Release Syndrome (Cytokine Storm), Fibrosarcoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hematological Tumor, Hepatocellular Carcinoma, Juvenile Myelomonocytic Leukemia (JMML), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Lung Disease, Lymphoma, Malignant Pleural Effusion, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neurotoxicity Syndromes, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Osteoarthritis, Ovarian Cancer, Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma and Unspecified.

Furthermore, this report also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
• The report reviews Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Abhelix LLC, H1 2020
Pipeline by Aduro BioTech Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by BioInvent International AB, H1 2020
Pipeline by BriaCell Therapeutics Corp, H1 2020
Pipeline by Cold Genesys Inc, H1 2020
Pipeline by Cytonus Therapeutics Inc, H1 2020
Pipeline by Epeius Biotechnologies Corp, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Humabs BioMed SA, H1 2020
Pipeline by Humanigen Inc, H1 2020
Pipeline by I-Mab Biopharma Co Ltd, H1 2020
Pipeline by Izana Bioscience Ltd, H1 2020
Pipeline by Morphotek Inc, H1 2020
Pipeline by Seagull Labs (I) Pvt Ltd, H1 2020
Pipeline by Sillajen Biotherapeutics, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Abhelix LLC
Aduro BioTech Inc
Amgen Inc
AstraZeneca Plc
BioInvent International AB
BriaCell Therapeutics Corp
Cold Genesys Inc
Cytonus Therapeutics Inc
Epeius Biotechnologies Corp
GlaxoSmithKline Plc
Humabs BioMed SA
Humanigen Inc
I-Mab Biopharma Co Ltd
Izana Bioscience Ltd
Morphotek Inc
Seagull Labs (I) Pvt Ltd
Sillajen Biotherapeutics